A 16,600-D outer membrane protein is present in all strains of Haemophilus influenzae and antibodies to this protein are present in human serum. This study was designed to assess the role of this outer membrane protein (P6) in nontypeable H. influenzae as a target for human serum bactericidal antibody. P6 was isolated and coupled to an affinity column. Depleting normal human serum of antibodies to P6 by affinity chromatography resulted in reduced bactericidal activity of that serum for nontypeable H. influenzae. Immunopurified antibodies to P6 from human serum were bactericidal. Finally, preincubation of bacteria with a monoclonal antibody that recognizes a surface epitope on P6, inhibited human serum bactericidal killing. Taken together, these experiments establish that P6 is a target for human bactericidal antibodies. This observation provides evidence that P6 plays a potentially important role in human immunity to infection by nontypeable H. influenzae.
Introduction
The incidence of infection due to nontypeable Haemophilus influenzae has been underestimated for years. Over the past five to seven years, a substantial body of literature has established that this bacterium is an important pathogen in both adults and children (1) (2) (3) (4) (5) (6) . Nontypeable H. influenzae is a major cause of respiratory infections in adults, particularly in chronic bronchitis (1, 6) . It causes '20% of all episodes of acute otitis media in children (4). In addition, nontypeable H. influenzae causes a variety of other less common infections, such as meningitis, postpartum sepsis, neonatal sepsis, sinusitis, and others (1) (2) (3) (7) (8) (9) . With the recognition ofthis bacterium as an important human pathogen, investigation has focused on understanding the pathogenesis of and immunity to infection, with an ultimate goal of prevention of these infections.
Since the presence of bactericidal antibodies in serum is related to protection from infection due to H. influenzae type b (10) and encapsulated meningococci (11), there has been interest in studying bactericidal antibody to nontypeable H. influenzae in human serum. Indeed, there is evidence that bactericidal antibody is related to protection from otitis media caused by the Address reprint requests to Dr. Murphy at the Division of Infectious Diseases, Erie County Medical Center, 462 Grider Street, Buffalo, NY 
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Receivedfor publication 17 March 1986 and in revisedform 23 June 1986. bacterium. Shurin et al. (12) demonstrated that the absence of bactericidal antibody to a strain of nontypeable H. influenzae in the sera of children is associated with susceptibility to otitis media due to nontypeable H. influenzae. Identifying surface structures that are targets of human bactericidal antibody is important in understanding human immunity and could direct efforts in vaccine development.
Previous work from our laboratory has identified a 16,600-D outer membrane protein (OMP)' that contains an epitope present in all of 150 strains tested ofH. influenzae, both typeable and nontypeable (13) . Antibody to this OMP is present in human serum. The current study establishes that this 16,600-D OMP (P6) is a target of human bactericidal antibodies.
Methods
Bacterial strains. Nontypeable H. influenzae strains 3524 and 1479 were isolated from the sputum of two adults with chronic bronchitis at the Erie County Medical Center, Buffalo, NY. The identity of the species of the strains was confirmed by colonial morphology and growth requirement for hemin and nicotinamide adenine dinucleotide. The isolates were confirmed as nontypeable by counterimmunoelectrophoresis with use of reference strains and antiserum from the Centers for Disease Control (14) . Strains were stored in Mueller-Hinton broth plus 10% glycerol at -700C.
Sources of antibodies. Pooled normal human serum (pNHS) was obtained from six healthy adults in Buffalo, NY. Two individual normal human serum samples were obtained from healthy adults in Buffalo (NHS-1) and Boston, MA (NHS-2). Neither of these was part of pNHS.
Sera from Buffalo were heated at 560C for 30 min to inactivate complement and stored in aliquots at -20'C. NHS-2 from Boston was stored at -70'C and thawed just prior to use.
Mouse monoclonal antibody 7F3 is an IgG3 immunoglobulin and recognizes an epitope on P6; this epitope.is present in all strains of H.
influenzae. Antibody 7F3 has been characterized in detail elsewhere (13) . Monoclonal antibody 3D2 recognizes an epitope on lipid A of H. influenzae; it has been described elsewhere (15 10 ,000 g for 20 min at 40C. The supernatants were pooled and centrifuged at 80,000 g for 2 h at 40C. The clear, gel-like pellets were suspended in distilled water and lyophilized. The resulting powder is referred to as outer membrane complex, which consists of OMPs and LOS (17, 18) .
To separate P6, outer membrane complex was suspended in buffer B (0.5 mg/ml) and incubated at 370C for 30 min. The insoluble material was removed by centrifugation at 100,000 g for 60 min at 370C. The pellet was resuspended, incubated, and centrifuged in the same way two more times. The pellets, which contained P6, were subjected to SDSpolyacrylamide gel electrophoresis (PAGE) and Western blot analysis.
To solubilize P6, the pellets were suspended in buffer B, incubated at 60'C for 30 min and centrifuged at 100,000 g for 60 min at 370C. The protein concentration in the supernatant (which contained P6), was determined by measurement of the optical density at 280 nm (OD280) using a standard curve with bovine serum albumin (BSA) in buffer B. For each measurement a new standard curve was constructed using BSA at 0.125, 0.25, 0.50, 1.0, and 2.0 mg/ml. These consistently yielded a linear curve and showed minimal day-to-day variability. Measurements of the protein concentration of the same P6 solution on different days were highly reproducible. Each 100 mg (dry weight) of outer membrane complex yielded -1 mg (by OD28O) of P6.
SDS-PAGE. P6 and whole cell preparations were subjected to SDS-PAGE with 13.2% separating gels. Preparations were heated at 100°C for 5 min in sample buffer containing 0.06 M Tris, 1.2% SDS, 1 or 5% beta mercaptoethanol, 11.9% glycerol, and 0.003% bromophenol blue. Gels were subjected to Coomassie Blue stain (14) , silver stain (17) was measured for 3 min, and the change in OD460 per minute was calculated. The substrate was prepared by dissolving 10 mg of O-dianisidine-2HCl (Sigma Chemical Co., St. Louis, MO) in 1 ml of methanol plus 1 ml of substrate buffer (0.05 M NaHCO3 adjusted to pH 5.0 with glacial acetic acid). 1.67 ml of this was then added to 0.1 ml of 3% H202 and substrate buffer was added to a final 100-ml vol.
Controls were run with each set of K-ELISAs. A cuvette for each conjugate was "coated" with sensitization buffer only (no antigen), followed by serum, conjugate, and substrate as described above. In the other set ofcontrols, PBS-tween was used in place ofserum (no antibody) and the other steps were performed as described. These controls consistently showed little or no background. K-ELISAs were performed in duplicate and the mean of the two values was calculated. Affinity chromatography. P6 was coupled to an affinity column. Solubilized P6 was isolated as described above and SDS was partially removed from the preparation using Extracti-Gel D (Pierce Chemical Co., Rockford, IL), equilibrated with buffer B that was lacking SDS. The protein was then promptly dialyzed overnight against coupling buffer (0.1 M NaHCO3, 0.5 M NaCG, 0.5% Zwittergent, pH 8.3). 1 g ofcyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) was swelled with 1 mM HCG in a sintered glass funnel. After washing once with coupling buffer, the gel was transferred to a flask containing 4 mg of P6 in 8 ml of coupling buffer. This was shaken at room temperature for 2 h. The slurry was placed back in the sintered glass funnel and the liquid was aspirated. The protein content in this liquid was 2 mg indicating that -2 mg of P6 was coupled on to the column. The gel was washed and then shaken overnight at 4VC in 0.2 M glycine, pH 8.0 to block remaining active groups. Excess adsorbed protein was washed away with coupling buffer alternating with 0.1 M sodium acetate, 0.5 M NaCG, pH 4.0. The gel was placed in a column and equilibrated with PBS. This is referred to as the P6 column. A second column was made simultaneously in which coupling buffer was used in place of P6 in coupling buffer. All other manipulations were identical to those of the P6 column. This second column is referred to as the control column.
To deplete human serum of antibody to P6, 4 ml of a 1:5 dilution in PBS of serum was applied to the affinity columns. All effluent fractions were collected until OD2go measurements were no longer detected. These fractions were pooled, dialyzed against Gey's balanced salt solution and concentrated to 2 ml by pressure filtration. These effluents from both the P6 and control columns were subjected to Western blot assay, K-ELISA, and bactericidal assay.
To immunopurify human serum antibody to P6, 40 ml of a 1:5 dilution in PBS of pNHS was run over the affinity column over -3 h. After washing the columns with 100 ml of PBS, the immunoadsorbed antibody was eluted with I ml of 0.2 M glycine, pH 2.5. The affinity column was coupled in tandem with a Biogel P-30 desalting column equilibrated with PBS to remove glycine. I-ml fractions were collected and the OD2so was monitored. No protein peak was detected by OD280 measurements (sensitivity -20 gg/ml). When performing affinity chromatography using this method in other systems, immunoglubulin elutes in fractions 4 through 9. Therefore, these fractions were pooled and dialyzed against Gey's balanced salt solution. This is referred to as eluate. For each serum sample subjected to affinity chromatography on the P6 column, the identical method was performed with the control column.
Eluates from both columns were tested in bactericidal assay, Western blot assay, and K-ELISA.
Bactericidal Assay
REAGENTS. Nontypeable H. influenzae. Strain 3524 was grown to midlogarithmic phase in freshly prepared brain heart infusion broth supplemented with hemin (10 ,g/ml) and nicotinamide adenine dinocleotide (10 jg/ml). An aliquot was diluted to S X 104 colony-forming units (CFU) per ml in 10% BSA in Gey's balanced salt solution. A 42-Ad amount of this dilution was used in a total reaction volume of 250 ,ul. Therefore, -2,000 CFU were present in the reaction mixture in each bactericidal assay.
Complement. Both a negative and positive control were included in each experiment. The negative control consisted of complement source and bacteria with no added antibody to assure that the organisms maintained their viability and that the complement source was not killing. The positive control consisted of heat-inactivated serum, complement source, and bacteria to assure that complement was active. In addition, for each serum fraction from the P6 column, the analogous fractions from the control column were assayed such that the same log phase bacteria were tested concurrently with fractions from the two columns. Fig. 2 is a Western blot assay in which a whole cell preparation and P6 preparation are tested with three antisera. It shows that P6 contains the 7F3 epitope (13) and that the preparation contains no detectable LOS using monoclonal antibody 3D2. Antibody 3D2 detects nanogram quantities of LOS in this assay (15, 17 (Fig. 2) . When subjected to SDS-PAGE, the apparent molecular weight of P6 in the isolated preparation was slightly higher than the apparent molecular weight of P6 in the whole cell preparation. This is most obvious in Fig. 2 . This difference probably results from some alteration of the protein during the isolation procedure.
Analysis ofNHS depleted ofantibody to P6. pNHS and NHS-1 were subjected to affinity chromatography over the P6 and control columns. Effluents from the two columns were studied in Western blot assay in equivalent dilutions to determine whether the P6 column specifically depleted the NHS samples of antibody to P6. Fig. 3 shows that the P6 column removed antibodies to P6 from human serum and the control column did not remove antibodies to P6. In addition, antibodies to other proteins were present in the effluents indicating that the P6 column specifically depleted serum of antibodies to P6. The bands in lanes A through D of Fig. 3 were detected using protein Aperoxidase conjugate. Anti human IgM-peroxidase failed to detect antibody to P6 in whole pNHS and NHS-I by Western blot assay.
K-ELISAs were performed to quantitate the difference in antibody titer to P6 in the effluents from the two columns. Table  I Bactericidal assays were performed to determine whether depleting human serum of antibody to P6 resulted in a change in bactericidal activity of that serum. Bactericidal assays were initially performed with varying concentrations of whole NHS-1 and pNHS to determine the minimum concentrations that demonstrated bactericidal activity. Effluents were assayed at these concentrations. This was done to ensure that excess bactericidal antibody was not present in the bactericidal reaction mixture so that the assay would detect a change in the amount ofbactericidal antibody. For NHS-1 a concentration of 15% serum was chosen and for pNHS, a concentration of 20% was chosen. Fig. 4 shows the results of bactericidal assays for NHS-l effluents tested at concentrations equivalent to 15% serum. At this concentration, P6 column effluent showed no bactericidal activity for strain 3524, whereas the control column effluent had bactericidal activity similar to that ofwhole serum. Fig. 5 shows the results of bactericidal assays for pNHS column effluents assayed in concentrations equivalent to 20% serum. The P6 column effluent showed less bactericidal activity than the corresponding effluent from the control column. Therefore, depleting NHS-l and pNHS of antibody to P6 reduces bactericidal activity ofthe sera for strain 3524.
Upon initial examination, Figs. 4 and 5 might appear to indicate that much or all of human serum bactericidal antibody is directed at P6. As noted above, however, these assays were performed with serum concentrations near the endpoint ofbactericidal killing. If these sera were assayed at higher concentra- tions, the difference between P6 and control effluents would be less striking due to the presence ofhigher concentrations ofbactericidal antibody to other surface antigens. Analysis ofimmunopurified antibody to P6. Antibody to P6 in eluates from the affinity columns was quantitated in K-ELISA. Table I shows that a substantial titer of IgM antibody to P6 was present in the P6 column eluate while none was detected in the control column eluate. Using protein A-peroxidase conjugate, a small amount of IgG antibody to P6 was detected in the P6 column eluate. The eluates were subjected to Western blot assay using whole cell preparations. No antibody to P6 or other antigens was detected by Western blot with protein A-peroxidase or anti-human IgM peroxidase (Fig. 3) . Fig. 6 illustrates the results of bactericidal assays using immunopurified antibody to P6 as the source of antibody. When used at a concentration of75%, P6 column eluate produced 90% killing in 2 h. None of the eluates from the control column demonstrated bactericidal activity when assayed concomitantly using the identical method. Results of control experiments indicate that killing was antibody directed and complement mediated. First, control column eluate that contained no detectable antibody to P6, but was otherwise identical to the P6 eluate showed no killing. Second, controls containing organisms, complement, and diluent with no added antibody produced no killing. Third, controls containing organisms, 75% P6 eluate and diluent with no added complement produced no killing.
Inhibition of human bactericidal antibody by monoclonal antibody 7F3. We attempted to inhibit serum killing of 3524 with monoclonal antibodies 7F3 and 3D2 in order to (a) confirm that P6 is a surface-exposed outer membrane antigen, (b) to assess if P6 might serve as an acceptor site in situ for human bactericidal antibody, and (c) to ascertain ifinhibition by monoclonal antibody was specific or possibly the result of steric inhibition due to screening of nearby bactericidal antibody targets. Fig. 7 shows the results of bactericidal inhibition assays in which strain 3524 was preincubated with dilutions of protein A purified monoclonal antibodies 7F3 and 3D2 before the addition of NHS-2 and complement to the reaction mixtures. These experiments demonstrated that preincubation of bacteria with 7F3 inhibited human serum bactericidal killing while preincubation with antibody 3D2 had no effect on killing. which recognizes an epitope on P6 inhibits bactericidal activity ofhuman serum for nontypeable H. influenzae. Taken together, these observations indicate that P6 is a human bactericidal locus. Antibody to P6 in affinity column effluents and eluates were quantitated using a K-ELISA system (Table I) . A K-ELISA was chosen because it offers advantages over conventional endpoint ELISA. First, K-ELISA is based on enzyme rate kinetics and yields quantitative linear data on antigen or antibody concentration. When antigen is present in excess, the results ofK-ELISA are linear with regard to antibody concentration (19) . In endpoint ELISA, enzyme concentration is linear with respect to activity only during the brief initial phase of the reaction and then only when the enzyme concentration is lower than that of substrate (19) . A second advantage of K-ELISA is that background activity is minimal. In the experiments described here, control cuvettes consistently showed little or no activity. Finally, in our hands, K-ELISA shows better day-to-day reproducibility than endpoint ELISA. We have shown previously that the assay yields highly reproducible results when measuring antibody to outer membrane antigens of nontypeable H. influenzae in rabbit antisera (17) and mouse monoclonal antibodies (19) . The results ofassays in the present study indicate that K-ELISA is a reliable method for quantitating antibody to P6 in human serum as well.
Analysis of column effluents by K-ELISA and Western blot assay indicated that the P6 column depleted serum of both IgG and IgM antibody to P6 compared to the control column. However, analysis of column eluates indicated that very little IgG antibody was eluted from the column. Protein A-peroxidase did not detect antibody to P6 or other antigens in the P6 column eluates in Western blot assays in spite of clear-cut evidence of depletion of antibody to P6 by the P6 column ( Fig. 3 and Table  I ). A possible explanation for this observation is that IgG antibody to P6 remained bound to the column and could not be eluted. An alternative explanation is that the eluting conditions denatured the IgG antibody so that it lost its activity.
Results of K-ELISA suggest that the antibodies to P6 in the P6 column eluates are predominantly IgM (Table I) . These antibodies are detected by K-ELISA but not by Western blot assay. The inability of Western blot assay to detect IgM antibody in the P6 column eluate is consistent with the observation that IgM antibody to P6 is not detected in whole serum in Western blot assay. A possible explanation for this is that human IgM antibody to P6 does not bind well on nitrocellulose. An alternative explanation is that the determinants on P6 to which human IgM antibodies bind are not exposed when the protein is immobilized on nitrocellulose.
The possibility that small amounts of contaminating bactericidal antibodies to antigens other than P6 were bound to and eluted from the P6 column exists. However, this possibility is unlikely. In addition, the inhibition of human bactericidal antibody by antibody 7F3 represents an independent line of evidence that does not depend on fractionation of serum antibodies by affinity chromatography.
In the experiments involving inhibition of human bactericidal antibody 7F3 inhibits bacterial killing by binding to the epitope on P6. These experiments confirm that P6 antigen is surface exposed and that it may be a target, in situ for human bactericidal antibody.
Experiments were performed to determine ifthe addition of purified P6 antigen to bactericidal reaction mixtures would inhibit human bactericidal killing by immunoabsorbing P6 directed antibody, thereby making it unavailable for killing. Con (28) (29) (30) . Indeed, Munson and Granoff (16) The presence of P6 in the outer membrane of H. influenzae has been noted by several groups of investigators and has been the subject of recent investigation (13, 14, 16, 33, 34) . It makes up a relatively small proportion of the total protein content of the outer membrane. Munson and Granoffestimated by weight that the P6-peptidoglycan fraction made up 5% of the outer membrane (16) . Solubilized P6, apparently free of peptidoglycan comprised -1% ofthe outer membrane in this study. This may be an underestimation because P6 is not completely insoluble in 1% SDS buffer at 370C since a band at 16,600 D is visible when the 1% SDS buffer-soluble fraction is subjected to SDS-PAGE. P6 appears to stain weakly with Coomassie Blue. SDSgels that show a rather faintly staining band with Coomassie Blue show a prominent band in Western blot assay with human serum or monoclonal antibody 7F3. A portion of the OMP is exposed on the surface of the bacterium since P6 is accessible to bactericidal antibody, monoclonal antibody 7F3 and rabbit antisera stain the organism by immunofluorescence, and absorbed antiserum immunoprecipitates P6 from whole organisms (16) . P6 contains an epitope common to all strains of H. influenzae tested thus far; this epitope is a highly specific marker for H. influenzae since the epitope is absent in virtually all other bacterial species tested (13) . Antibody to P6 is present in human serum as demonstrated in Western blot assay and K-ELISA. It is worthy of note that the band is among the most prominent recognized by antibody in human serum in Western blot assay despite the relatively small amount of the protein in the outer membrane. Future studies will be directed at determining the function of the OMP, studying the antigenic heterogeneity or conservation ofthis OMP among strains, identing the relevant epitopes on the protein, and determining whether P6 is a human bactericidal locus in type b strains. This will lead to further elucidation ofthe role ofP6 in human immunity to infection caused by H. influenzae.
